DAWN (Day One Biopharmaceuticals) 5-Year Sharpe Ratio: N/A (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DAWN Day One Biopharmaceuticals Inc DAWN
12 GF Score
Price $21.53
! 5 Warning Signs
View Full Analysis

What is Day One Biopharmaceuticals 5-Year Sharpe Ratio?

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2026-09-21), Day One Biopharmaceuticals's 5-Year Sharpe Ratio is Not available.

Day One Biopharmaceuticals  (NAS:DAWN) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Day One Biopharmaceuticals 5-Year Sharpe Ratio Related Terms

DAWN vs TYRA, DFTX, MLYS: 5-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Day One Biopharmaceuticals's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Day One Biopharmaceuticals 5-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Day One Biopharmaceuticals's 5-Year Sharpe Ratio falls into.


DAWN
12GF Score
Day One Biopharmaceuticals Inc DAWN
5-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Day One Biopharmaceuticals 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.

Day One Biopharmaceuticals Business Description

Address 1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score

Get the complete analysis for DAWN

5-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53
Price